Tomás Carminatti, Patricio Aitor García Marchiñena, Ignacio Pablo Tobia González, Valeria de Miguel, Marcelo Martín Serra, Pablo Germán Kalfayan, Alberto Manuel Jurado
{"title":"Hereditary Renal Cell Carcinoma: Is Age an Independent Criterion for Genetic Testing? A Large Cohort from a Latin America Referral Center.","authors":"Tomás Carminatti, Patricio Aitor García Marchiñena, Ignacio Pablo Tobia González, Valeria de Miguel, Marcelo Martín Serra, Pablo Germán Kalfayan, Alberto Manuel Jurado","doi":"10.15586/jkcvhl.v10i3.242","DOIUrl":null,"url":null,"abstract":"<p><p>Although age younger than 46 years has been an independent criterion for genetic testing in hereditary renal cell carcinoma (hRCC), there is a lack of evidence in the literature. This study aims to analyze whether a 46-year-old cut-off should be considered an independent genetic testing criterion and to elucidate risk factors predicting a positive genetic test. Observational study from January 2010 to December 2021. All patients under 46 years with a non-metastatic kidney mass and surgical indication were included. We assume patients who relapse in the first 5 years of follow-up could have a positive genetic test. As risk factors for relapse, ergo positive genetic test, we consider those patients who presented multifocal, bilateral, or previous renal tumor. Of 2,232 nephrectomies for kidney cancer, 301 patients met the inclusion criteria. The median follow-up was 60 months (IQR 29-101). The estimated five-year RFS was 94.4% (95% CI 91.3-97.5). Tumor size, previous renal tumor, multifocality, bilaterality, and pT3 or pT4 stage were independent recurrence risk factors. Genetic testing was performed on 24 patients. 10 patients had pathogenic variants in the test, 8 of which recurred during their life. 46-year-old cut-off has shown low performance in genetic testing. Therefore, we recommend that it be considered only if other hRCC risk criteria exist. Multifocality, bilaterality, and previous renal tumor could predict a positive genetic test.</p>","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"10 3","pages":"17-22"},"PeriodicalIF":1.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404984/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Kidney Cancer and VHL","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15586/jkcvhl.v10i3.242","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Although age younger than 46 years has been an independent criterion for genetic testing in hereditary renal cell carcinoma (hRCC), there is a lack of evidence in the literature. This study aims to analyze whether a 46-year-old cut-off should be considered an independent genetic testing criterion and to elucidate risk factors predicting a positive genetic test. Observational study from January 2010 to December 2021. All patients under 46 years with a non-metastatic kidney mass and surgical indication were included. We assume patients who relapse in the first 5 years of follow-up could have a positive genetic test. As risk factors for relapse, ergo positive genetic test, we consider those patients who presented multifocal, bilateral, or previous renal tumor. Of 2,232 nephrectomies for kidney cancer, 301 patients met the inclusion criteria. The median follow-up was 60 months (IQR 29-101). The estimated five-year RFS was 94.4% (95% CI 91.3-97.5). Tumor size, previous renal tumor, multifocality, bilaterality, and pT3 or pT4 stage were independent recurrence risk factors. Genetic testing was performed on 24 patients. 10 patients had pathogenic variants in the test, 8 of which recurred during their life. 46-year-old cut-off has shown low performance in genetic testing. Therefore, we recommend that it be considered only if other hRCC risk criteria exist. Multifocality, bilaterality, and previous renal tumor could predict a positive genetic test.
尽管年龄小于46岁一直是遗传性肾细胞癌(hRCC)基因检测的独立标准,但在文献中缺乏证据。本研究旨在分析是否应将46岁的截止年龄视为独立的基因检测标准,并阐明预测基因检测阳性的危险因素。2010年1月至2021年12月的观察研究。所有年龄在46岁以下且有非转移性肾肿块和手术指征的患者均纳入研究。我们假设在前5年随访中复发的患者可能有阳性基因检测。作为复发的危险因素,因此基因检测阳性,我们考虑那些有多灶性、双侧或既往肾肿瘤的患者。在2232例因肾癌而行肾切除术的患者中,301例患者符合纳入标准。中位随访时间为60个月(IQR 29-101)。估计5年RFS为94.4% (95% CI 91.3-97.5)。肿瘤大小、既往肾肿瘤、多灶性、双侧、pT3或pT4分期是独立的复发危险因素。对24例患者进行基因检测。10名患者在测试中发现致病变异,其中8名患者在其一生中复发。46岁的截止年龄在基因检测中表现不佳。因此,我们建议只有在存在其他hRCC风险标准的情况下才考虑它。多灶性、双侧性和既往肾肿瘤可预测基因检测阳性。